"von Willebrand Factor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A high-molecular-weight plasma protein, produced by endothelial cells and megakaryocytes, that is part of the factor VIII/von Willebrand factor complex. The von Willebrand factor has receptors for collagen, platelets, and ristocetin activity as well as the immunologically distinct antigenic determinants. It functions in adhesion of platelets to collagen and hemostatic plug formation. The prolonged bleeding time in VON WILLEBRAND DISEASES is due to the deficiency of this factor.
| Descriptor ID |
D014841
|
| MeSH Number(s) |
D12.776.124.125.920 D23.119.985
|
| Concept/Terms |
von Willebrand Factor- von Willebrand Factor
- Factor VIIIR-Ag
- Factor VIIIR Ag
- Factor VIIIR-RCo
- Factor VIIIR RCo
- Ristocetin-Willebrand Factor
- Ristocetin Willebrand Factor
- von Willebrand Protein
- Factor VIII-Related Antigen
- Factor VIII Related Antigen
- Ristocetin Cofactor
|
Below are MeSH descriptors whose meaning is more general than "von Willebrand Factor".
Below are MeSH descriptors whose meaning is more specific than "von Willebrand Factor".
This graph shows the total number of publications written about "von Willebrand Factor" by people in this website by year, and whether "von Willebrand Factor" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 1 | 0 | 1 |
| 2002 | 0 | 2 | 2 |
| 2003 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2006 | 1 | 0 | 1 |
| 2007 | 1 | 0 | 1 |
| 2008 | 1 | 0 | 1 |
| 2009 | 1 | 2 | 3 |
| 2014 | 0 | 1 | 1 |
| 2016 | 1 | 0 | 1 |
| 2018 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "von Willebrand Factor" by people in Profiles.
-
Verbree-Willemsen L, Zhang YN, Gijsberts CM, Schoneveld AH, Wang JW, Lam CSP, Vernooij F, Bots ML, Peelen LM, Grobbee DE, Raichlen JS, de Kleijn DPV. LDL extracellular vesicle coagulation protein levels change after initiation of statin therapy. Findings from the METEOR trial. Int J Cardiol. 2018 Nov 15; 271:247-253.
-
Favaloro EJ, Bonar R, Hollestelle MJ, Jennings I, Mohammed S, Meijer P, Woods T, Meiring M. Differential sensitivity of von Willebrand factor activity assays to reduced VWF molecular weight forms: A large international cross-laboratory study. Thromb Res. 2018 06; 166:96-105.
-
Zhu S, Tomaiuolo M, Diamond SL. Minimum wound size for clotting: flowing blood coagulates on a single collagen fiber presenting tissue factor and von Willebrand factor. Integr Biol (Camb). 2016 08 08; 8(8):813-20.
-
Zhang P, Policha A, Tulenko T, DiMuzio P. Autologous human plasma in stem cell culture and cryopreservation in the creation of a tissue-engineered vascular graft. J Vasc Surg. 2016 Mar; 63(3):805-14.
-
Zhang P, Baxter J, Vinod K, Tulenko TN, Di Muzio PJ. Endothelial differentiation of amniotic fluid-derived stem cells: synergism of biochemical and shear force stimuli. Stem Cells Dev. 2009 Nov; 18(9):1299-308.
-
Sgueglia GA, Niccoli G, Spaziani C, Cosentino N, Russo E, Andreotti F, Lanza GA, Landolfi R, Crea F. Baseline von Willebrand factor plasma levels and no-reflow phenomenon after primary percutaneous coronary intervention for ST segment elevation myocardial infarction. Int J Cardiol. 2010 Nov 19; 145(2):230-232.
-
Jennings I, Kitchen DP, Woods TA, Kitchen S, Walker ID, Preston FE. Laboratory performance in the World Federation of Hemophilia EQA programme, 2003-2008. Haemophilia. 2009 Mar; 15(2):571-7.
-
Krishnan S, Siegel J, Pullen G, Hevelow M, Dampier C, Stuart M. Increased von Willebrand factor antigen and high molecular weight multimers in sickle cell disease associated with nocturnal hypoxemia. Thromb Res. 2008; 122(4):455-8.
-
Calvin DP, Hammond ME, Pajak TF, Trotti AM, Meredith RF, Rotman M, Jones CU, Byhardt RW, Demas WF, Ang KK, Fu KK. Microvessel density >or=60 does not predict for outcome after radiation treatment for locally advanced head and neck squamous cell carcinoma: results of a correlative study from the Radiation Therapy Oncology Group (RTOG) 90-03 Trial. Am J Clin Oncol. 2007 Aug; 30(4):406-19.
-
Kitchen S, Jennings I, Woods TA, Kitchen DP, Walker ID, Preston FE. Laboratory tests for measurement of von Willebrand factor show poor agreement among different centers: results from the United Kingdom National External Quality Assessment Scheme for Blood Coagulation. Semin Thromb Hemost. 2006 Jul; 32(5):492-8.